MRI-visible nanoparticles from hydrophobic gadolinium poly(&#949;-caprolactone) conjugates by Porsio, B. et al.
lable at ScienceDirect
Polymer 56 (2015) 135e140Contents lists avaiPolymer
journal homepage: www.elsevier .com/locate/polymerMRI-visible nanoparticles from hydrophobic gadolinium
poly(ε-caprolactone) conjugates
Barbara Porsio a, Laurent Lemaire b, Sarah El Habnouni a, Vincent Darcos a,
Florence Franconi c, Xavier Garric a, Jean Coudane a, Benjamin Nottelet a, *
a Institut des Biomolecules Max Mousseron (IBMM), UMR CNRS 5247, University of Montpellier 1, University of Montpellier 2,
Faculty of Pharmacy, 15 Av. C. Flahault, Montpellier 34093, France
b Micro et Nanomedecines BiomimetiquesdMINT, INSERM UMR-S1066, Universite Angers, 4 rue Larrey, 49933 Angers Cedex 9, France
c PRIMEX, Universite Angers, 4 rue Larrey, 49933 Angers Cedex 9, Francea r t i c l e i n f o
Article history:
Received 2 October 2014
Received in revised form
10 November 2014
Accepted 11 November 2014
Available online 21 November 2014
Keywords:
Nanoparticles
MRI
Polyester* Corresponding author.
E-mail address: benjamin.nottelet@univ-montp1.f
http://dx.doi.org/10.1016/j.polymer.2014.11.031
0032-3861/© 2014 Elsevier Ltd. All rights reserved.a b s t r a c t
In this work we report on the synthesis of two hydrophobic and degradable gadolinium poly(ε-capro-
lactone) conjugates and their use for the preparation of MRI-visible nanoparticles intended for diagnosis
applications. Advantage has been taken from functional poly(ε-caprolactone)s (PCL) bearing propargyl
(PCL-yne) or amine groups (P(CL-co-NH2VL)) to yield conjugates by following two strategies. In a ﬁrst
approach, an azido-chelate of gadolinium (Gd(III)) has been conjugated by CuAAC to PCL-yne to yield a
polymeric chelate containing 2.6 wt% of Gd(III). In a second approach, a dianhydride Gd(III)-ligand was
reacted with P(CL-co-NH2VL) to yield, after complexation with Gd(III) salts, a polymeric chelate con-
taining 15.4 wt% of Gd(III). The polymers biocompatibility was assessed against L929 ﬁbroblasts. In a
second part, advantage was taken from the PCLs conjugates hydrophobicity to easily prepare by nano-
precipitation nanoparticles with diameters ranging from 120 to 170 nm. The nanoparticles MRI-visibility
was then evaluated and conﬁrmed under the spin-echo and the clinically relevant gradient-echo MRI
sequences.
© 2014 Elsevier Ltd. All rights reserved.1. Introduction
Magnetic resonance imaging (MRI) is the leading imaging
technique to provide high spatial and temporal resolutions in
clinical diagnosis and enhance the detection and characterization
of lesions within the body [1]. In this frame, MRI-visible nano-
particles are proposed for early tumor diagnosis (especially in
liver), thrombus diagnosis, as well as for their potential as platform
for multifunctional biomedical applications with simultaneous
drug-delivery and imaging capabilities [2,3]. Polymeric nano-
particles are generally associated with negative contrast agents
(CAs), that contain ferrous superparamagnetic compounds (T2/T2*
agents), or positive CAs, that contain paramagnetic elements (e.g.,
gadolinium Gd(III)) (T1 agents), embedded or grafted to the ma-
terials. T1 agents are however generally preferred over T2/T2*
agents as they induce a positive enhancement of the signal by
modulating the longitudinal relaxation time of the water protons inr (B. Nottelet).the tissues [4]. This explains why the blood pool agents currently
approved for clinical uses are mainly based on hydrophilic and low
molecular weight Gd(III) chelates (Magnevist®, Dotarem®, Omnis-
can™) that are injected prior to MRI scanning in order to increase
the signal. However, large amounts of these potentially toxic
contrast agents are needed per injection [5]. Various strategies have
therefore been proposed to address this problem in particular with
water soluble macromolecular contrast agents (MMCAs) that are
known to remain in the vascular system for a longer period, and
may thus provide a longer imaging window and a more favorable
signal-to-noise ratio. In addition, polymeric systems are believed to
allow higher sensitivity by increasing the relaxivity of Gd(III)-CAs
and allow modulating the pharmacokinetics of Gd(III)-CAs [6].
More in details, a common strategy to get higher relaxivity relies
on the reduction of Gd(III)-CAs tumbling rate in solution. This can
be obtained by the design of polymeric systems whose higher
conformational rigidity over low molecular weight chelates is ex-
pected to restrict the internal rotation of the Gd(III)-CA [7]. MMCAs
with multiple Gd(III) centres have thus extensively been studied
[4,8,9], and include water-soluble polycondensates of chelates
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[14e20], or amphiphilic copolymeric conjugates able to self-
assemble into the form of coreeshell micelles [21e26]. However,
one drawback resides in the limited relaxivity enhancements
because of the ﬂexibility of the copolymers used, especially poly(-
ethylene oxide), and the fact that Gd(III) centers are in most cases
linked as chain-ends moieties, which limits their conformational
restriction. In that sense, crosslinked structures can be an inter-
esting alternative to slow down Gd(III) centers rotational motions
[27]. The use of hydrophobic polymer backbone bearing Gd(III)
centers to generate MRI nanoparticles may be another alternative
as recently illustrated by our group [28e30]. Indeed, although hy-
drophobic environment do not favor the formation of hydration
sphere and water molecule exchanges between the inner and
second hydration sphere, it could be of beneﬁt to provide a more
constraint environment [31]. This approach is to date limited to the
use nanoparticles made of FDA approved hydrophobic, non-
cytotoxic and biodegradable polyesters like PLA and PLGA to
encapsulate Gd(III) chelates. However, hydrophilic low-molecular
weight Gd(III) chelates incorporated into PLGA micro- or nano-
spheres have been shown to rapidly diffuse out leading to a loss of
MRI-visibility [2,31e34]. To avoid this, surface modiﬁcation of PLGA
nanospheres was recently proposed by Ratzinger et al. who
immobilized diethylenetriaminepentaacetic acid (DTPA) and
1,4,7,10-tetraazacyclododecane-1,4,7,10-tetraacetic acid (DOTA) li-
gands on spacers prior to Gd(III) chelation [35]. Although very
promising, two main drawbacks were reported. First, Gd(III) ﬁnal
dose was highly dependent on the type of ligation, with efﬁcient
loading obtained only with poly(ethylenimine) spacers leading to
coreeshell amphiphilic structures. Second, extensivewashes had to
be performed by successive dialyses to eliminate the non com-
plexed Gd(III) which resulted in partial degradation of the PLGA
particles.
The present work aims at an alternative strategy for the prep-
aration of MRI-visible nanoparticles directly generated from orig-
inal multivalent PCL-based MMCAs. By contrast with others
MMCAs, we take advantage of two multifunctional PCLs, namely a
propargylated PCL and an aminated PCL, to yield hydrophobic PCL-
based multicenters MMCAs by CuI-catalyzed [3 þ 2] cycloaddition
(CuAAC) and amidiﬁcation reaction, respectively. MMCAs are
characterized in particular with respect to their Gd(III) content and
their cytocompatibility. Thanks to their hydrophobicity, the PCL
MMCAs are then used to easily prepare MRI-visible nanoparticles
that are characterized in terms of size and surface charges. Finally,
the nanoparticles MRI-visibility is evaluated in vitro under the spin-
echo and the clinically relevant gradient-echo MRI sequences.
2. Materials and methods
2.1. Materials
Benzyl alcohol, ε-caprolactone and toluene were dried over
calcium hydride for 24 h at room temperature and distilled under
reduced pressure. Tetrahydrofuran (THF) was dried by reﬂuxing
over a benzophenoneesodium mixture and distilled. All other
chemicals were obtained from Aldrich and were used without any
further puriﬁcation. Deuterated chloroform (CDCl3) and dimethyl
sulfoxide (DMSO6D) were purchased from Eurisotop (Saint-Aubin,
France). Spectra/Por dialysis tubes (cut-off 1000, 3500, 5000 g/mol)
were purchased from Spectrum Labs (Breda, The Netherlands).
PrestoBlue™, Dulbecco's Modiﬁed Eagle Medium (DMEM ⁄ F-12),
Phosphate Buffered Saline (PBS), sterile Dulbecco's Phosphate
Buffered Saline (DBPS), Fetal Bovine Serum (FBS), penicillin,
streptomycin, and glutamine were purchased from Invitrogen
(Cergy Pontoise, France). BD Falcon™ Tissue Culture Polystyrene(TCPS) 24-well plates were purchased from Becton Dickinson (Le
Pont de Claix, France).
2.2. Characterization
1H NMR and 13C NMR spectroscopy was performed on a Bruker
spectrometer (AMX300) operating at 300 MHz and 75 MHz,
respectively. Deuterated chloroform or deuterated dimethyl sulf-
oxidewere used as solvents. Chemical shifts were expressed in ppm
with respect to tetramethylsilane (TMS).
Infrared spectroscopy was performed on a Perkin Elmer Spec-
trum 100 FT-IR spectrometer using the attenuated total reﬂectance
(ATR) technique.
Size exclusion chromatography (SEC) was performed at room
temperature on a Waters system equipped with a guard column, a
600 mm PLgel 5 mmMixed C column (Polymer Laboratories), and a
Waters 410 refractometric detector. Calibration was established
with poly(styrene) standards from Polymer Laboratories. THF was
used as eluent at a ﬂow rate of 1 mL min1.
LC/MS analyses were performed on a Q-TOF (Waters) spec-
trometer ﬁtted with an electrospray interface. Solvents used for
HPLC and LC/MSwere HPLC grade. MALDI analyses were performed
on a Ultra-Flex III (Bruker) spectrometer using a dithranol matrix.
Gd(III) quantiﬁcation was performed on an Element XR sector
ﬁeld ICP-MS (inductively coupled plasma-mass spectrometry) at
Geosciences in Montpellier (University Montpellier II). Internal
standardization used an ultra-pure solution enriched with indium.
Particle size and zeta potential determinationwere performed on
a Zetasizer Nano ZS (Malvern Instrument, UK). For mean particle
size and polydispersity index (PDI) measurements, the samples
were diluted in milliQ water. For zeta potential analyses, the sam-
ples were diluted in milliQ water or PBS (pH ¼ 7.4). Solutions were
ﬁltered through a 0.45 mm ﬁlter. All measurements were performed
in triplicate.
Transmission electron microscope (TEM) micrographs were ob-
tained with a JEOL 1200 EXII (working voltage of 120 kV). A drop of
nanoparticles solution was placed onto a carbon-supported copper
grid for 5 min. The excess liquid was removed by capillarity with a
ﬁlter paper. Mean particle size was determined by measuring the
particles diameter with Image J software (Rasband, W.S., ImageJ, U.
S. National Institutes of Health, Bethesda, Maryland, USA, http://
imagej.nih.gov/ij/, 1997e2012).
2.3. Synthesis of MRI-visible P(CL[DTPA(Gd)]) 3
3 was prepared by reaction between poly(a-propargyl-ε-capro-
lactone-co-ε-caprolactone)s P(Pg-CL) 2 (FaPrεCL ¼ 5%, MnSEC ¼
25000 g mol1. Ð ¼ 1.9) and a clickable Gd(III) chelate (diN3-
DTPA(Gd(III))) 1 (full synthetic details for compounds 1 and 2 can be
found in the Supporting Information). Brieﬂy, copolymer 2, complex
1 (3 eq./aPgεCL units) and CuBr (2eq./aPgεCL units) were solubilized
in a large amount of dimethylformamide (DMF). The solution was
degassed by three freezeepumpethaw cycles. N,N,N0,N00,N00-pen-
tamethyldiethylenetriamine (PMDETA) (2eq./aPgεCL units)
degassed by argon bubbling was added to the reactionmedium. The
reactionwas carried out for 48 h at room temperature under stirring.
The crude medium was dissolved in THF for dialysis (CO
3500 gmol1) against distilledwater. 3was recovered after removal
of the solvents anddried invacuo. The contentof complexedGd(III) in
3was quantitatively determined by ICP-MS: 2.6 wt%.
2.4. Synthesis of MRI-visible P(CL-co-VL[DTPA(Gd)]) 5
5 was prepared by reaction between poly(ε-caprolactone-co-5-
amino-d-valerolactone) P(CL-co-NH2VL) 4 (FNН2-VL ¼ 33%,
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thetic details for compound 4 can be found in the Supporting In-
formation). More in details, a solution of DTPA dianhydride
(162.1 mg, 1.2 eq. with respect to NH2 groups) in anhydrous DMF
was added dropwise to a solution of 4 (100 mg, 0.37 mmol of NH2)
in a large amount of anhydrous DMF (4 mL) and in the presence of
triethylamine (0.1 mL; 3eq. with respect to NH2 groups). The re-
action was left to stir for 24 h at room temperature under an inert
atmosphere of argon. The resulting polymer was puriﬁed by dial-
ysis against an HCL solution (0.1 M) and distilled water (CO
1000 g mol1). The polymer was ﬁnally recovered by freeze-drying
in good yield (205 mg). The extent of amidiﬁcationwas determined
by 1H NMR analysis (60% yield). 1H NMR (300 MHz; DMSO-d6),
d (ppm): 4.00 (m,eCH2eO)NH-VL & εCL, 3.75 (CH2eCH(NH2)eCH2)NH-
VL, 3.60e3.00 (NeCH2, CH2eCH(N)eCH2)NH-VL & DTPA, 2.20e2.40
(COeCH2eCH2)NH-VL & εCL, 1.70 (CH2eCH2eCH(N))NH-VL, 1.30e1.60
(CH2eCH2eCH2eCH2eCH2)εCL.
Complexation of themacromolecular ligandwith Gd(III) was then
carried out. In a typical experiment, the copolymer (100 mg,
9.3105mol ofmono-amideDTPA)was solubilized inDMSO (5mL)
before addition of GdCl3-6H2O (63 mg, 1.9  104 mol, 2eq. with
respect to mono-amide DTPA). Complexation was let to run for four
days under stirring at 40 C. The polymerwas puriﬁed by dialysis (CO
1000 gmol1) againstmethanol for 24 h before ﬁnal recovery of 5 by
solvent removal under reduced pressure. The content of complexed
Gd(III) in 5was quantitatively determined by ICP-MS: 15.4 wt%.
2.5. Preparation of MRI-visible nanoparticles
Nanoparticles were prepared with a concentration of Gd(III) of
0.1 wt%with respect to PCL. In a typical experiment, 477.5mg of PCL
(MnSEC ¼ 35 000 g/mol, Ð ¼ 1.86), 22.5 mg of 3 and 180 mg of
SPAN®80 were dissolved in 90 mL of acetone. This organic solution
was added dropwise to an aqueous phase containing Tween®80
(360 mg in 180 mL) under magnetic stirring and at room temper-
ature. The mixture was left under stirring for 2 h to form the
nanoparticles by solvent diffusion. Acetone and part of the water
were eliminated at 30 C under reduced pressure to a ﬁnal sus-
pension volume of 100 ml. The suspension was dialyzed for 24 h
against distilled water (CO ¼ 5000 g/mol) before freeze-drying and
recovery of the nanoparticles (NP3) in good yield (83%).
Similar conditions were used to prepare nanoparticles (NP5)
from polymer 5 with adjusted ratios of PCL and 5.
2.6. MR imaging protocols
MR imaging experiments were performed on a Bruker Biospec
70/20 system operating at a magnetic ﬁeld of 7T (Bruker, Wissem-
bourg, France). The resonant circuit of the NMR probewas a 35-mm
diameter birdcage resonator. MRI nanoparticles, under the form of
small clusters, were embedded in a degassed 1% (w/w) agarose gel
prior to imaging. To test signal enhancement, samples were
analyzed using either a three-dimensional (3-D) acquisition with
relaxation enhancement (RARE) sequence (TR ¼ 3000 ms; mean
echo time (TEm) ¼ 8 ms; RARE factor ¼ 8; FOV ¼ 3  3  1.5 cm;
matrix 128  128  64) in which T1 weighting was introduced into
the MR images using an inversion pulse (inversion time was set at
1100ms, sufﬁcient to allowcanceling of the embedding gel) or a 3D-
gradient echo sequence (TR ¼ 110 ms; TE ¼ 3 ms; a ¼ 60;
FOV ¼ 3  3  1.5 cm; matrix 128  128  64).
2.7. In vitro cytocompatibility
Murine ﬁbroblasts cells (designated L929) were used to assess
the in vitro cytocompatibility of the materials as recommended bythe International and European Standards (ISO 10993-5:2009).
L929 cells were cultured in DMEM alpha supplemented with 10%
Fetal Bovine Serum (FBS), penicillin (100 U/mL), streptomycin
(100 mg/mL) and glutamine (2 mM). Sample disks (ø 15 mm) were
cut from copolymer ﬁlms and disinfected in ethanol for 30 min
before immersion in a solution of sterile PBS containing penicillin
and streptomycin (1 mg/mL) and incubation for 48 h at 37 C. Films
were then rinsed 2 times with sterile PBS before soaking for 12 h in
sterile PBS. After disinfection, disks were placed in TCPS 12-well
plates and Viton® O-rings were used to maintain the samples on
the bottom of the wells and avoid cells growing on TCPS under-
neath the samples. Disks were ﬁnally seeded with 1.104 cells and
viability was evaluated after 1, 2 and 3 days using PrestoBlue®
assay, which reﬂects the number of living cells present on a surface
at a given time point. At scheduled time points, culture medium
was removed and replaced by 1mL of freshmedium containing 10%
of PrestoBlue®. After 2 h of incubation at 37 C, 200 mL of super-
natant were taken from each well and analyzed for ﬂuorescence at
530 nm (ex.) and 615 nm (em.) with a Victor X3 (Perkin Elmer).
3. Results and discussions
3.1. Synthesis of the PCL MMCAs
The objective of the present work was to propose an alternative
strategy to hydrophilic MMCAs or mixtures of low molecular
weight CAs and polymermatrices for the preparation ofMRI-visible
nanoparticles. In addition, attention was paid to provide MRI-
visible nanoparticles that would also be degradable and biocom-
patible. Therefore, two multivalent hydrophobic PCL MMCAs have
been prepared (Scheme 1).
In a ﬁrst approach, the ligation chemistry between the PCL
backbone and the Gd(III) chelate was based on azide-alkyne Huis-
gen cycloaddition. An azide-functionalized bis-amide DTPA(Gd(III))
chelate (1) and PCL-yne (2) have been prepared and used for the
CuAAC according to a previously reported methodology [29].
Thanks to the high efﬁciency of the click chemistry ligation and of
the use of a preformed clickable Gd(III) chelate, this strategy allows
to ﬁnely tune the ﬁnal Gd(III) content as well as the density of
Gd(III) chelate along the polymer backbone. To ensure MRI-
visibility of the targeted MMCA, a PCL containing 5 mol% of prop-
argylated units (MnSEC ¼ 25,000 g mol1. Ð ¼ 1.9) was synthesized
and conjugated to the azide-functionalized bis-amide DTPA(G-
d(III)). This composition was chosen to yield a ﬁnal Gd(III) content
of ca. 2 wt%, as it was shown in previous studies that this ratio
provides a good MRI signal enhancement while minimizing the
overall loading of the toxic Gd(III) species [29]. The copolyesters
were characterized before and after ligation by 1H NMR analyses
(Supporting Information Fig. S1). The ﬁnal content of Gd(III) in 3
was determined by ICP-MS and found to be 2.6 wt% in the copo-
lyester to be compared with the targeted 2.1 wt%. This small
discrepancy may be due to an initial underestimation of the
propargyl group content, resulting from the low intensity of the
signal corresponding to the methine proton of the propargyl in the
1H NMR spectra.
In a second approach, the ligation chemistry between the PCL
backbone and the Gd(III) chelate was based on the reaction be-
tween the primary amine groups of poly(ε-caprolactone-co-5-
amino-d-valerolactone) [36,37] (P(CL-co-NH2VL)) and the acti-
vated carboxylic groups of DTPA dianhydride to yield an original
Gd(III)/PCL amide conjugate. P(CL-co-NH2VL) (4) was synthesized
by ring opening polymerization of εCL and amino-protected 5-Z-
amino-d-valerolactone (NHZ-VL), followed by the acidic recovery of
the free amine groups. Themolar ratio of NH2-VLwas 33%while the
ﬁnal molecular weight was MnSEC ¼ 6000 g mol1 with Ð ¼ 1.2
Scheme 1. Preparation of MRI-visible PCL nanoparticles: i) CuBr, PMDETA, DMF, RT, 48 h; ii) (PCL, 2, SPAN®80, acetone)/(Tween®80, water), RT, 2 h; iii) DTPA dianhydride, Et3N,
DMFan, RT, 24 h and GdCl3-6H2O, DMSO, 40 C, 4 days; iv) (PCL, 5, SPAN®80, acetone)/(Tween®80, water), RT, 2 h.
Fig. 1. L929 proliferation on PCL MMCAs ﬁlms compared to PCL ﬁlms and TCPS
(positive control) (data are expressed as means ± SD and correspond to measurements
in triplicate).
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the PCL MMCAwas obtained in two steps by reaction of 4 with the
Gd(III) ligand, namely DTPA dianhydride, and the subsequent
complexation of the macromolecular ligand with GdCl3-6H2O. 1H
NMR analysis was used to evaluate the extent of DTPA grafting on 4
(Supporting Information Fig. S2b). By comparison between the in-
tensities of the signals at d ¼ 3.0e3.50 ppm corresponding to the
methylene protons ofmono-amide DTPA and of themethine proton
of NH2-VL units and the signal at d¼ 4.00 ppm corresponding to the
methylene protons of εCL and NH2-VL units, a 60% yield was
calculated. 5 was ﬁnally obtained by complexation of GdCl3-6H2O
with the PCL macroligand. The ﬁnal content of Gd(III) in 5 was
determined by ICPMS and found to be 15.4 wt% in good accordance
with the expected value of 14.7 wt%.
3.2. In vitro cytocompatibility of PCL MMCAs
Tests were conducted on the L-929 ﬁbroblasts cell line, as rec-
ommended by International and European standards [38]. Cyto-
compatibility of the MRI-visible polymers was assessed on ﬁlms
containing the same gadolinium concentration (0.1 wt%) as the one
used in the MRI-visible nanoparticles (see 3.3 and 3.4). In addition,
higher concentrations (0.4 wt% and 1 wt%) were also evaluated for
ﬁlms preparedwith 5 as thisMMCAwas evaluated for the ﬁrst time.
Cell proliferation and its extent were compared with TCPS culture
plates and PCL ﬁlms controls. As shown in Fig. 1 the presence of PCL
MMCAs 3 and 5 did not impede ﬁbroblast proliferation. At a 0.1wt%
Gd(III) concentration, similar results were observed for 3 and 5
although their chemical nature and ligation strategies were
different. Although lower than on TCPS control, proliferations
occurred on ﬁlms prepared with 3 or 5. They were similar, if not
higher, to the ones observed on pristine PCL, which is widely
recognized as a biocompatible material. The same trend was
observed for ﬁlms prepared from 5 and having a higher (0.4 wt%)
Gd(III) concentration. Only at the high 1.0 wt% Gd(III) concentration
a lower proliferation was observed. Two conclusions may bepointed out from these results. First, concentrations of Gd(III)
should be kept low to guaranty a maximal cytocompatibility. This
should not be a problem considering the good MRI-visibility ob-
tained with the lowest 0.1 wt% Gd(III) concentration (see 3.4).
Secondly, taking into account the similar proliferation obtained
with MRI-PCLs compared to PCL, the former would appear to be
suitable for the growth of ﬁbroblasts and cell-contacting
applications.
3.3. MRI-visible nanoparticles
Nanoparticles were prepared by nanoprecipitationwith acetone
and water as a miscible solvents mixture. An overall concentration
of Gd(III) equal to 0.1 wt% was targeted and obtained by mixing
deﬁned amounts of pristine PCL and MRI-visible PCLs 3 and 5. In
Table 1
Mean particle size and zeta potential of PCL and MRI-visible PCL nanoparticles.
Particles Mean particle
size [nm]
PDIa Zeta potential [mV] Gd/PCL
[wt%]
mQ water PBS
PCL 123 ± 6a
(55 ± 15)b
0.236 ± 0.012 38 5 0
P(CL[DTPA(Gd)]) NP3 153 ± 11a
(71 ± 18)b
0.276 ± 0.016 46 8 0.1
P(CL-co-VL[DTPA(Gd)]) NP5 170 ± 24a
(80 ± 20)b
0.246 ± 0.055 25 9 0.1
a Determined by DLS.
b Determined by TEM image analysis.
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nanoparticles were also prepared. Dynamic light scattering (DLS)
measurements showed diameter of nanoparticles ranging from 120
to 170 nmwith polydispersities around 0.250 (Table 1, Fig. S3). The
distribution of nanoparticles obtained by DLS was in agreement
with the one reported in the literature under the same conditions
and may be due to the presence of few larger aggregates as seen in
TEM pictures [39]. Images obtained by TEM show spherical nano-
particles with a moderate size-distribution (Fig. 2). Image analyses
gave relatively smaller diameters compared to DLS measurements,
typically in the range 55e80 nm. This difference is attributed to the
presence of few larger nanoparticles aggregates (see Fig. S4) that
may form as a result of the hydrophobicity of the PCL and that are
known to inﬂuence DLS measurements in the intensity mode.
Zeta potential of the nanoparticles was measured for all systems
in milliQ water and in PBS (Table 1). All nanoparticles had a nega-
tive zeta potential with values ranging from 46 mV to 25 mV in
water and from 9 mV to 5 mV in PBS. These negative values are
classically observed for PCL nanoparticles, likely due to the surface
exposure of carboxylate groups of the chain-ends at the surface
[40]. In addition, in NP3 and NP5 the mono-amide DTPA carboxylic
groups are also exposed. The presence of bis-amide DTPA in
copolymer 3 decreased the zeta potential of NP3 compared to PCL
nanoparticles as shown by a ca. 10 mV decrease. In opposition, the
presence of partially protonated amine groups in PCL-co-
VLDTPA(Gd) resulted in a shift of the zeta potential of NP5 to-
wards less negative values, with a 10 mV increase compared to PCL.
Upon addition of salts in PBS medium and as a result of charge
screening, zeta potential values drifted towards more neutral
values while remaining negative.
3.4. Nanoparticles MRI-visibility
MRI-visibility of the nanoparticles (0.1 wt% of Gd(III)) was
evaluated by embedding them in agarose gel prior to MRI experi-
ments. NP3 and NP5 showed a positive T1 signal enhancement
both in spin-echo (SE) (Fig. 3a) and gradient-echo (GE) sequence
(Fig. 3b), which is of importance when considering that GEFig. 2. TEM micrographs of (a) PCL nanoparticles (b) P(CL[DTPA(Gd)]) nasequences are clinically used. The longitudinal relaxation times T1
of the water protons in the surroundings of the nanoparticles were
ﬁrst measured. Theywere found equal to 310ms in the surrounding
of NP3 and 890 ms in the surrounding of NP5, to be compared to
2500 ms for the water protons in the genuine gel. It is remarkable
that with concentrations of Gd(III) as low as 0.1 wt% the particles
were highly visible. This conﬁrms that hydrophobic PCL MMCAs
may allowMR imaging with low Gd(III) concentration compared to
the current clinical bolus injections of commercial DTPA/Gd(III)
contrast agents (0.1 mmol/kg). It should be noted that no direct
comparison between T1 and relaxivities of the MRI-visible nano-
particles and of conventional water soluble small molecular weight
DTPA/Gd(III) contrast agents was considered. Indeed, as a direct
consequence of their hydrophobic nature, aggregates of NP3 and
NP5were found in the gel, which bans these studies that are based
on concentration dependent analyses of homogeneous aqueous
solutions or dispersions. However, it is possible to compare the
longitudinal relaxation times T1 measured in the surrounding of
the nanoparticles with the one of DTPA/Gd(III) solutions. T1 forNP3
(310ms) andNP5 (890ms) roughly corresponds toT1 of 1.6mmol/L
and 0.8 mmol/L solution of DTPA/Gd(III), respectively, which cor-
responds to concentrations used in clinic [2]. In the frame of further
studies, dual modiﬁcation of functional PCLs with DTPA derivatives
and low extents of poly(ethylene oxide) chains should be consid-
ered to allow the nanoparticles dispersion without aggregation
while guarantying the overall hydrophobic character of the
polymers.
MR imaging was ﬁnally carried out on the same samples after
storage for a prolonged period of 18 months at 4 C. Lower rows in
Fig. 3a and b shows the signal observed for NP3 and NP5 after
storage. It is to note that under the same MRI experiment condi-
tions, the T1 signal enhancement was similar to the one initially
observed. Moreover, as the signal of the gel did not signiﬁcantly
change with time and that no diffusion in the gel was observed, it
may be assumed that no release of Gd(III) occurred, which quali-
tatively conﬁrms the stability of the macromolecular contrast
agents. Of course under physiological conditions different results
may be expected, but this result is in agreement with a previousnoparticles NP3 and (c) P(CL-co-VL[DTPA(Gd)]) nanoparticles NP5.
Fig. 3. Spin echo (a) and gradient echo (b) MR-imaging at t0 and after 18 months storage. (AeC) P(CL-co-VL[DTPA(Gd)]) nanoparticles NP5 aggregates; (BeD) P(CL[DTPA(Gd)])
nanoparticles NP3 aggregates (MRI ﬁeld 7 T).
B. Porsio et al. / Polymer 56 (2015) 135e140140study carried out on ﬁlms prepared with compound 3 that
demonstrated a good stability at 37 C (PBS, pH 7.4) with only 0.1%
of the total amount of Gd(III) released after 6 months from
ﬁlms [29].
4. Conclusion
In this work we reported on two hydrophobic and degradable
PCL MMCAs that were successfully synthesized for the straight-
forward preparation of MRI-visible nanoparticles. The two strate-
gies, convergent click chemistry and divergent amidiﬁcation, led to
MMCAs suitable for the preparation of MRI-visible nanoparticles
containing 0.1wt% Gd(III) and exhibiting hydrodynamic diameters
in the range 120e170 nm. Although different in nature, all nano-
particles turned to be MRI-visible independently of the MRI
sequence used, in particular when using the clinically relevant
gradient-echo sequence. Although this ﬁrst study should be
completed in the near future by additional experiments (degrada-
tion assays, toxicity evaluation of NP, hydrophilization of NP sur-
faces, in vitro/in vivo evaluation), we believe that the proposed PCL
MMCAs represent an attractive platform for the preparation of
degradable theranostic agents and could open the way to new
diagnostic tools.
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